JNJ (Johnson & Johnson) 3-Year FCF Growth Rate : -2.80% (As of Sep. 2024)

View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson 3-Year FCF Growth Rate?

Johnson & Johnson's Free Cash Flow per Share for the three months ended in Sep. 2024 was $2.35.

During the past 12 months, Johnson & Johnson's average Free Cash Flow per Share Growth Rate was 29.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -0.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Johnson & Johnson was 45.50% per year. The lowest was -4.60% per year. And the median was 10.65% per year.

Competitive Comparison of Johnson & Johnson's 3-Year FCF Growth Rate

For the Drug Manufacturers - General subindustry, Johnson & Johnson's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's 3-Year FCF Growth Rate falls into.

Johnson & Johnson 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Johnson & Johnson (NYSE:JNJ) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Johnson & Johnson 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Bulgaria JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Executives

Robert J Decker	officer: Controller, CAO	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Vanessa Broadhurst	officer: EVP, Global Corp Aff.	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert	officer: EVP, WW Chair, Pharmaceuticals	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Timothy Schmid	officer: EVP, WW Chair, MedTech	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait	officer: See Remarks	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo	officer: VP, Worldwide Human Resources	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel	officer: EVP, Chief GSC Officer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed	officer: EVP, Pharmaceuticals R&D	ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson	officer: EVP, Chief Information Officer	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk	officer: Exec VP, CFO	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy	officer: EVP, WW Chair, Medical Devices	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon	officer: Exec VP, WW Chair, Consumer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard	officer: Executive VP, General Counsel	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk	director	855 S. MINT STREET, CHARLOTTE NC 28202